Hyperhomocysteinemia predicts cardiovascular outcomes in
determining the high mortality of patients with end-stage hemodialysis patients.
renal disease (ESRD) is complex because of the high
Background. We prospectively tested the prediction power prevalence of multiple risk factors [2] . Hyperhomocysof homocysteinemia for all-cause and cardiovascular outcomes teinemia was suspected as a cardiovascular risk factor in a cohort of 175 hemodialysis patients followed for 29 Ϯ 12 in chronic renal failure in the eighties [3] , and the probmonths.
Methods. Survival analysis was performed by the Cox's prolem was examined in several cross-sectional and mechaportional hazard model and data were expressed as hazard nistic studies [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In this regard, the observations that ratio and 95% confidence interval (CI).
plasma homocysteine is independently related to aortic
Results. During the follow-up period 51 patients died, 31 of stiffness [19] and left ventricular hypertrophy [20] are them (61%) of cardiovascular causes and 16 patients developed of particular interest. However, apart from the seminal non-fatal atherothrombotic complications. Plasma total homostudies by Bostom et al [21] and Moustapha et al [22] cysteine was an independent predictor of cardiovascular mortality (P ϭ 0.01). Combined analysis of fatal and non-fatal in a total of 240 patients, there is a lack of prospective atherothrombotic events showed that homocysteine was a investigations linking hyperhomocysteinemia to cardiostrong and independent predictor of these outcomes because vascular mortality in hemodialysis patients. The issue is the risk of these events was 8.2 times higher (95% CI 1.9 to relevant mainly because a recent study suggested that 32.2) in patients in the third homocysteine tertile than in those reduced plasma homocysteine concentration, rather than in the first tertile (P ϭ 0.005).
hyperhomocysteinemia, predicts survival in these pa-
Conclusions.
There is a clear association between hyperhomocysteinemia and incident cardiovascular mortality and athtients [23].
erothrombotic events in hemodialysis patients. Intervention
Our current study prospectively tested the association studies are needed to determine whether the accumulation of between plasma total homocysteine and all-cause and carthis substance has a causal role in the pathogenesis of cardiovasdiovascular outcomes in a large cohort of hemodialysis cular damage in patients undergoing hemodialysis.
patients. Since cardiovascular risk is inherently multifactorial, the role of hyperhomocysteinemia was analyzed in multivariable models encompassing traditional and Cardiovascular disease accounts for approximately 50% nontraditional risk factors and factors peculiar to ESRD. of mortality among patients on chronic dialysis and a similarly high mortality rate has been observed in the United States and in Europe [1] . The appreciation of METHODS the relative role of traditional (that is, Framingham risk Protocol factor) and nontraditional cardiovascular risk factors in
The protocol conformed to the ethical guidelines of our Institutions and informed consent was obtained from One hundred seventy-five patients with ESRD (98 males and 77 females, all Caucasians) who had been on  2002 by the International Society of Nephrology regular dialysis treatment (RDT) for at least six months fibrinogen, total homocysteine, B 6 , B 12 , folate and hemoand without clinical evidence of overt cardiovascular conglobin was obtained from all patients during a mid week gestion [24] were eligible for the study. These patients non-dialysis day. Plasma total homocysteine was deterrepresented about the 70% of the entire hemodialysis mined by a high-pressure liquid chromatography (HPLC) population of four dialysis units. The remaining patients method based on a derivative of SBD-F (ammonium-7-were excluded from the study because they were taking fluorobenzo-2-oxa-1,3-diazole-4-sulfonate) fluorescence folic acid, vitamin B 6 and B 12 supplements (11%), or be- [25] . CRP was measured by using a commercially availcause of frank cardiovascular congestion or overt inable kit (immunoturbidimetric method, lower limit of defections (9%), or because they were hospitalized for tection Յ3.5 mg/L; Behring, Scoppito, L'Aquila, Italy). inter-current illnesses (10%). The prevalence of diabetes Vitamin B 6 was measured by a radioenzymatic assay for mellitus in this cohort was 16% (that is, 28 out of 175 direct measurement of plasma pyridoxal 5Ј-phosphate patients).
[26] and plasma folate and vitamin B 12 by commercially All patients were virtually anuric (24-hour urine volavailable competitive immunoassays (direct chemilumiume Ͻ200 mL/day) and were being treated thrice weekly nescence; Chiron Diagnostic, San Francisco, CA, USA). with standard bicarbonate hemodialysis (Na 138 mmol/L, HCO 3 ). Dry weight was targeted in that is, 3 measurements/week) taken during the month each case to achieve a normotensive edema-free state.
preceding the study was considered as a representative Sixty-one patients were on anti-hypertensive treatment of the BP of each patient [27] . [46 on mono-therapy with angiotensin-converting enzyme (ACE) inhibitors, angiotensin II type 1 (AT-1)
Statistical analysis receptor antagonists, calcium channel blockers, alphaData are reported as mean Ϯ SD or as median and and beta-blockers, and 15 were on double therapy with inter-quartile range. Comparisons between groups were various combinations of these drugs]. Sixty-five patients made by the t test or by the Mann-Whitney test, as approwere habitual smokers (20 Ϯ 15 cigarettes/day).
priate. Independent correlates of plasma homocysteine were identified by univariate and multivariate linear reFollow-up study gression analysis. Variables that had an independent reAfter the initial assessment patients were followed up lationship with plasma homocysteine were ordered acfor 29 Ϯ 12 months. During the follow-up period fatal cording to their standardized effect, defined as regression and non-fatal cardiovascular events [electrocardiogram coefficient/standard error of the regression (␤). (ECG)-documented anginal episodes, myocardial infarc-
The independent prediction power of plasma total tion, heart failure, arrhythmia, transient ischemic attach, homocysteine for all-cause and cardiovascular outcomes stroke, and major arterial and venous thrombotic epiwas tested in Cox's proportional hazards models adsodes (except arteriovenous fistula thrombosis)] were acjusted for a series of traditional risk factors [age, sex, curately recorded. Myocardial infarction was confirmed diabetes, smoking, body mass index (BMI), systolic presby serial ECG evidence of a Q-wave or non-Q-wave sure and cholesterol], for emerging risk factors (CRP myocardial infarction and appropriate creatine phosphoand fibrinogen) and factors peculiar to ESRD [duration kinase MB fraction elevations. Thrombotic stroke was of regular dialysis treatment (RDT), hemoglobin, albuconfirmed by computerized tomographic imaging evimin and calcium*phosphate product]. Hazard ratios dence of cerebral infarction and/or neurological exami-(HR) and their 95% confidence intervals (CI) were calnation findings consistent with new-onset focal neurologculated with the use of the estimated regression coeffiical deficits lasting Ͼ24 hours. Each death was reviewed cients and their standard errors in the Cox's regression and assigned an underlying cause by a panel of five physianalysis. All calculations were made using a standard cians who were blinded to the potential independent statistical package (SPSS for Windows Version 9.0.1, predictor variables. As a part of the review process, all available medical information about each death was col-11 Mar 1999; SPSS, Chicago, IL, USA). lected. This information always included the study and hospitalization records. In the case of an out-of-hospital RESULTS death, family members were interviewed by telephone
The demographic, anthropometric, clinical and bioto better ascertain the circumstances surrounding death. chemical parameters of patients are given in Table 1 . In Laboratory measurements the entire group, plasma total homocysteine (median 28.9 mol/L, interquartile range 20.5 to 46.7 mol/L) A fasting blood sample for serum lipids, albumin, calcium and phosphate, C-reactive protein (CRP), plasma was above the upper limit of the normal range (cutoff the other hand, plasma homocysteine turned out to be an independent predictor of cardiovascular mortality, Univariate and multivariate correlates of plasma and the prediction power of plasma homocysteine for total homocysteine cardiovascular outcomes was also true when the analysis The univariate analysis showed that plasma total was confined to atherothrombotic events (Table 3 ) such homocysteine was inversely related to plasma folate (r ϭ as myocardial infarction, thrombotic stroke, mesenteric Ϫ0.30, P ϭ 0.0001) and plasma B 12 (r ϭ Ϫ0.21, P ϭ infarction and pulmonary embolism (these events were 0.02), and directly related to serum albumin (r ϭ 0.17, given in detail in Table 2 ). In this analysis a 10 mol/L P ϭ 0.03) and male sex (plasma total homocysteine in increase in plasma homocysteine was associated with a males was 32.2 mol/L, interquartile range 22.1 to 35% increase in the incident risk of fatal atherothrom-53.8 mol/L, and in females was 26.2 mol/L, 19.2 to botic events. Combined analysis of fatal and non-fatal 41.9 mol/L; P ϭ 0.03). In multivariate analysis plasma atherothrombotic events confirmed that homocysteine folate (␤ ϭ Ϫ0.28, P ϭ 0.001), serum albumin (␤ ϭ 0.28, was an independent predictor of these outcomes (Ta-P ϭ 0.009) and male sex (␤ ϭ 0.18, P ϭ 0.05) were ble 4). When patients were divided into three tertiles the only significant correlates of plasma homocysteine according to plasma homocysteine concentration, the (multiple R ϭ 0.48, P ϭ 0.0001) while plasma B 6 , plasma hazard ratio for fatal and non-fatal atherothrombotic B 12 , serum cholesterol, serum CRP, Kt/V, age, duration events was progressively higher from the first tertile onof RDT, smoking, diabetes, BMI, systolic pressure, and wards, and the hazard ratio of patients with plasma previous cardiovascular events were unrelated to plasma homocysteine in the third tertile was 8.2 times (95% CI homocysteine.
1.9 to 32.2) higher than in those in the first tertile (P ϭ 0.005; Fig. 1 ). Plasma total homocysteine, all-cause mortality and cardiovascular outcomes DISCUSSION During the follow-up period 51 patients died, 31 of them (61%) of cardiovascular causes (Table 2) , and 16 In a large cohort of patients with ESRD total plasma homocysteine predicted fatal cardiovascular events and patients developed non-fatal atherothrombotic complications (myocardial infarction in 2, angina in 3, retinal, established that the link between this risk factor and Data are expressed as hazard ratios, 95% CI (confidence interval) and P values. In the analysis of fatal atherothrombotic episodes deaths due to myocardial infarction, thrombotic stroke, mesenteric infarction and pulmonary embolism were included (see also second study, homocysteine was by 59% higher in dialysis patients who had fatal and non-fatal cardiovascular events, and the high cardiovascular risk conferred by this hyperhomocysteinemia was largely independent of traditional risk factors and unrelated to all-cause mortality [22] . In another study in hemodialysis patients homocysteine was associated with all-cause mortality [33] . In the current study, which was based on the largest hemodialysis cohort studied to date the trend towards total homocysteine predicting total mortality failed to attain statistical significance. Notably, in our study the risk of fatal cardiovascular complications was highly significant and coincided numerically (20% risk increase for each 10 mol/L increase in plasma total homocysteine; Table  3 ) with the estimate made in the study by Moustapha et al [22] . Although the biological mechanism(s) whereby humans has not been fully elucidated, it seems likely that mol/L; II tertile Ն 22 mol/L; III tertile Ն 37.8 mol/L. Data were this substance triggers cardiovascular events by causing adjusted for the other independent predictors of fatal and non-fatal atherothrombotic cardiovascular events (refer to Table 4 ).
oxidative injury to the endothelium and by altering the coagulation properties of the blood. In this regard, the strong link between homocysteine and atherothrombotic events found in our study seems relevant because it has cardiovascular outcomes was largely independent of traa plausible biological basis. [35] . Our study is the first to test phosphatemia and high calcium-phosphate product [32] . the prediction power of total homocysteine by adopting Hyperhomocysteinemia is found very frequently in dialysis patients [4-8, 13, 15, 21-23] . In the present study, a statistical approach taking into account other emerging multivariate analysis based on the main clinical and biorisk factors (namely CRP) and well-established risk facchemical indicators of the severity of uremia and on the tors peculiar to the uremic state, like anemia [31] and vitamins that regulate the metabolism of this amino acid hyperphosphatemia [32] . The fact that the relationship confirmed that serum folate is an independent correlate between hyperhomocysteinemia and cardiovascular of circulating homocysteine, which is in keeping with premortality and atherothrombotic events is independent vious observations [8, 1, 15] . Serum albumin is the main of these factors makes the epidemiological association carrier of circulating homocysteine, and a univariate relabetween this substance and cardiovascular complications tionship between homocysteine and serum albumin was in the dialysis population even more compelling. Our obnoted in a recent study in hemodialysis patients [23] .
servation also may help us better understand two recent Our multivariate analysis confirms that serum albumin is studies reporting a paradoxical link between hyperhomoan independent predictor of plasma total homocysteine. cysteinemia and survival in hemodialysis patients [18, 23] . The direct link between homocysteine and albumin ap-
The first was a small-scale study with a short follow-up pepears particularly important, because hypoalbuminemia riod and did not contemplate cardiovascular events and per se is a predictor of adverse cardiovascular outcomes death as primary end-points [18], while no statistical adand may therefore confound the effect of homocysteine justment for potential confounders and for traditional on these outcomes. Such a relationship highlights the comand non-traditional risk factors was performed in the plexity and inherent weakness of cross sectional studies second study [23] . aimed at establishing a link between cardiovascular risk
In conclusion, there is a clear association between hyperand the plasma concentration of this substance.
homocysteinemia and cardiovascular outcomes in dialThe issue as to whether hyperhomocysteinemia preysis patients. Homocysteine is, at least partially, a modidicts cardiovascular outcomes in hemodialysis patients fiable risk factor [36] . Intervention studies are needed was examined only in two studies. In the first study the to determine whether the accumulation of this substance cardiovascular risk was 3.6 times higher in patients with has a causal role in the pathogenesis of cardiovascular plasma homocysteine greater than 27 mol/L than in those displaying levels below this threshold [21] . In the damage in hemodialysis patients.
